Analysis of riluzole’s profile of use in a Central Hospital in Lisbon
Received 10 March 2018
Accepted for publication 12 May 2018
Published 6 November 2018 Volume 2018:12 Pages 2357—2361
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Ana Paróla,1 Fátima da Silva Mousinho de Palhares Falcão,1,2 Helena Farinha,1 André Caetano,3 Luís Santos,3 Elmira Medeiros,3 Miguel Viana-Baptista3,4
1Pharmacy Department, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal; 2Department of Social Pharmacy, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal; 3Neurology Department, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal; 4Faculty of Medical Sciences, Nova University of Lisbon, Lisbon, Portugal
Purpose: Riluzole is indicated to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS). Clinical studies have shown that this drug prolongs survival, defined as living patients who are not intubated for mechanical ventilation and without tracheotomy. The purpose of this study is to characterize riluzole’s use as well as the user population in order to contribute to a rational and safe use.
Patients and methods: Descriptive, observational, retrospective study describing and characterizing the use of riluzole in ALS patients between July 2006 and December 2016 conducted in a Lisbon’s Central Hospital.
Results: Over the course of the study period, 77 patients with different phenotypes of ALS received riluzole. The majority of patients (63%, n=49) were male. The median survival was 10.1 months, but 12 patients (16%) remained on therapy for more than 3 years; 65% of patients were lost to follow-up. The mean adherence rate was 91.2%, and the median adherence rate was 99.3%. One patient discontinued therapy due to gastrointestinal intolerance. Dyspnea and cough were the most common side effects, with roughly one third of patients experiencing each, followed by asthenia and hepatic effects.
Conclusion: Despite the extended enrollment period, only 77 patients met the criteria for study inclusion. Nonetheless, statistical data regarding our population is in accordance with reported international data. High adherence rates were observed, but 14% of patients discontinued riluzole. In such cases, assessment by a multidisciplinary team is warranted.
Keywords: riluzole, adherence rate, amyotrophic lateral sclerosis, safety profile, drug interactions
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]